AMPHASTAR PHARMACEUTICALS INC (AMPH)
Health Care · Generic and specialty injectable pharmaceuticals / inhalation drugs · NASDAQ
Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets.
What AMPHASTAR PHARMACEUTICALS INC does
Amphastar is a biopharmaceutical company that develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredients (APIs). The company currently markets over 25 prescription pharmaceutical products and one over-the-counter product (Primatene MIST®), with major products including BAQSIMI® (nasally administered glucagon for severe hypoglycemia), albuterol sulfate inhalation aerosol, iron sucrose injection, and teriparatide injection. Amphastar has built technological capabilities in peptide synthesis, complex molecule characterization, sustained-release technology, and manufacturing of various dosage formulations.
Themes: Generic injectables, Proprietary inhalation products, Glucagon / severe hypoglycemia treatment, Biosimilars / biological drug products, Drug delivery technologies, Active pharmaceutical ingredients (APIs), High-barrier-to-entry formulations, Respiratory / asthma / COPD treatments
Fundamentals
- Price$21.60 as of 2026-08-21 close
- Market cap$919M as of 2026-08-21
- 1-year return-27.2% 2025-08-21 close $29.66 → 2026-08-21 close $21.60
- P/E10.93 as of 2026-08-24
- Net margin+10.8% as of 2026-08-24
- Gross margin+47.7% as of 2026-08-24
- ROE+10.1% as of 2026-08-24
- Debt / equity0.80 as of 2026-08-24
- Revenue growth (YoY)+1.0% as of 2026-08-24
- Revenue CAGR (3y)+13.0% SEC XBRL
- Beta0.92 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How AMPH compares in its sector
- price-to-earnings ratiobottom 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AMPHASTAR PHARMACEUTICALS INC looks technically
AMPHASTAR PHARMACEUTICALS INC (AMPH) is trading 5.0% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 109 trading days ago — a "death cross", a bearish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 30.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 5.0% below its 200-day average, the long-term trend line — a long-term downtrend | -5.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $20.01 | $20.01 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $22.73 | $22.73 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 19.55. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 109 trading days ago — a "death cross", a bearish long-term signal | 109 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 21 (a reading of 25+ marks a strong trend) | 20.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 62, neither overbought (above 70) nor oversold (below 30) | 62.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($19.55 to $22.64) — its "stochastic" reading is 66 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 66.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $31.26 | $31.26 |
|---|---|---|
| From the 52-week high | it is 30.9% below its 52-week high (its highest price of the past year) | -30.9% |
| Above the 52-week low | it is 29.8% above its 52-week low (its lowest price of the past year) | +29.8% |
| Below the 52-week high | it is 30.9% below its highest point of the past year | 30.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $67.66 (set on 2023-08-09) | $67.66 |
| Given back of the 52-week move | over the past year its closes ranged ($16.87 to $30.81), and it has recovered roughly a third of its fall from last year’s high — 34% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $25.48 to $25.93. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 33.9% |
| From the all-time high | it is 68.1% below its all-time high | -68.1% |
| Nearest price level | it is trading 4.3% above a support level at $20.68 — a price it turned at twice since 2026-06-11, most recently on 2026-07-29. Since 2024-08-21 it has 4 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.3% |
| All-time low | its lowest closing price on record is $6.67 (set on 2014-06-25) | $6.67 |
| Above the all-time low | it is 223.8% above its all-time low | +223.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 82% of it) | 18th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7961 between its high and its low — about 3.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7961 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.18 and $21.84 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.18 – $20.51 – $21.84 |
| Typical daily range (% of price) | its price moves about 3.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.7% |
| Stretch from the 200-day average | it is trading 1.4 daily ranges below its 200-day average price (5.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.84× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Gap filled | a 13.5% gap up opened on 2026-08-07 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 9 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -0.64% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 7.9 percentage points (the stock gained 10.3% while the market gained 2.3%) | +7.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 15.8 percentage points (the stock gained 18.9% while the market gained 3.1%) | +15.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 35.4 percentage points (the stock lost 24.3% while the market gained 11.1%) | -35.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 47.7 percentage points (the stock lost 27.2% while the market gained 20.5%) | -47.7% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.4% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.8% of the share price. | +5.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $20.99 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +2.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $20.73 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +4.2% |
Price levels it has turned at before
AMPH last closed at $21.60 on 2026-08-21. Since 2024-08-21 it has turned at 4 prices below its last close and 12 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $20.68 | Support | 4.3% below the last close | turned there twice · 2026-06-11 to 2026-07-29 |
| $22.78 | Resistance | 5.5% above the last close | turned there four times · 2025-04-16 to 2026-08-07 |
| $20.28 | Support | 6.1% below the last close | turned there five times · 2025-07-18 to 2026-07-17 |
| $23.23 | Resistance | 7.5% above the last close | turned there twice · 2025-05-15 to 2026-04-20 |
| $19.55 | Support | 9.5% below the last close | turned there twice · 2026-05-28 to 2026-08-10 |
| $23.70 | Resistance | 9.8% above the last close | turned there twice · 2025-05-23 to 2025-11-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $19.55.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $23.66 and $26.20 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $19.55.
This reading has stood for 5 trading days, since 2026-08-17.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · lagging the market · Printed a doji candle · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (3.14 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$22.00 range $20.00 – $30.00; median $20.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AMPH
- Consensus EPS estimate$0.8519 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Supply chain concentration risk from single-source suppliers and reliance on third-party manufacturers for raw materials and APIs","Regulatory and FDA approval risks for product candidates and manufacturing operations, including timing and approval of pending ANDAs and biosimilar insulin candidates","Pricing pressure and reimbursement challenges from healthcare reforms, drug price controls, and competitive generic market dynamics"]
What changed in the latest 10-Q
AI-assisted comparison of AMPH's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- January 2026 License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for AMP-110 (corticotropin ACTH analog) with $2.0 million upfront payment (newer filing 2026-05-07)
- February 2026 FDA approval and April 2026 launch of Ipratropium Bromide HFA inhalation aerosol (newer filing 2026-05-07)
- Reference to Annual Report on Form 10-K for year ended December 31, 2025 (newer filing 2026-05-07)
- Three months ended March 31, 2026 compared to March 31, 2025 financial results section (newer filing 2026-05-07)
- Product revenue details for three months ended March 31, 2026 including individual product line changes and explanations (newer filing 2026-05-07)
- Mention of recently launched products including teriparatide launched in December 2025 (newer filing 2026-05-07)
- Removed:
- August 2025 FDA approval and Q3 2025 launch of Iron Sucrose Injection (older filing 2025-11-06)
- August 2025 License Agreement with Nanjing Anji Biotechnology Co., Ltd. and $6.0 million in earnest and upfront payments (older filing 2025-11-06)
- Reference to Annual Report on Form 10-K for year ended December 31, 2024 (older filing 2025-11-06)
- Three months ended September 30, 2025 compared to September 30, 2024 financial results section (older filing 2025-11-06)
- Product revenue details for three months ended September 30, 2025 (older filing 2025-11-06)
- Mention of "Other revenues" line item and Eli Lilly and Company sales accounting (older filing 2025-11-06)
- Reworded:
- Overview section changed from 'developing, manufacturing, marketing and selling' to 'developing, manufacturing, and commercializing' (newer 2026-05-07)
- Overview section changed from 'insulin API products' to 'active pharmaceutical ingredient, or API products' (newer 2026-05-07)
- Overview changed from listing '25 products' to 'over 25 prescription pharmaceutical products, and one over-the-counter product' with Primatene MIST mentioned separately (newer 2026-05-07)
- Overview product ranking changed from 'BAQSIMI, Primatene MIST, glucagon, epinephrine, and lidocaine' to 'BAQSIMI, Primatene MIST, epinephrine, glucagon, and lidocaine' (newer 2026-05-07)
- Overview changed from 'Three of the ANDAs and one biosimilar insulin candidate' to 'One ANDA and one biosimilar insulin candidate' (newer 2026-05-07)
- Overview changed from 'made several strategic acquisitions' to 'in-licensed several early-stage proprietary products and have made several strategic acquisitions' (newer 2026-05-07)
- Macroeconomic section reference year changed from 2024 to 2025 for Form 10-K (newer 2026-05-07)
- Notes:
- The newer filing (2026-05-07) covers Q1 2026 while older filing (2025-11-06) covers Q3 2025, making them non-comparable quarters
- Text in newer filing appears truncated at 'We anticipate that sales of glucagon will continu' suggesting additional content exists
- The comparison involves different fiscal periods and different financial tables, limiting direct comparability
Risk Factors
- Added:
- Newer filing references Annual Report on Form 10-K for year ended December 31, 2025 (added 2026-05-07)
- Removed:
- Older filing specified 'Amphastar Nanjing Pharmaceuticals, Ltd., or ANP' by name in Chinese subsidiary reference (removed 2026-05-07)
- Older filing referenced 'the timing for completion and the validation of the new construction at our ANP and Amphastar facilities' (removed 2026-05-07)
- Older filing referenced Annual Report on Form 10-K for year ended December 31, 2024 (removed 2026-05-07)
- Reworded:
- Chinese subsidiary reference changed from 'our expectations regarding the business of our Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Ltd., or ANP' to 'our expectations regarding the business of our Chinese subsidiary' (2026-05-07)
- New construction reference changed from 'the timing for completion and the validation of the new construction at our ANP and Amphastar facilities' to 'the timing for completion and the validation of the new construction at our facilities' (2026-05-07)
- Notes:
- Financial statements section shows different reporting periods (March 31, 2026 vs. September 30, 2025) but comparison focused on Risk Factors forward-looking statements section as requested
- The Item numbering for Risk Factors changed from page 41 (2025-11-06) to page 39 (2026-05-07), but substantive text changes in forward-looking statements are limited
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($345738) — 2 selling insiders
- Last 90 days0 buys · 2 sells ($345738) — 2 selling insiders
- Last 180 days0 buys · 2 sells ($345738) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-11. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AMPH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AMPH as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 7,669,492
- Reported value $150,245,351
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AMPH had 4,928,331 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AMPH had 11.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.89 days to cover at the same settlement.
- Reported short interest (shares) 4,928,331
- Short interest (% of shares outstanding) 11.6%
- Prior settlement (shares) 4,174,460
- Reported change 18.06%
- Days to cover (reported) 11.89
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sandoz (specialty generics and injectables)
- Baxter International (injectable pharmaceuticals)
- Hikma Pharmaceuticals (generic injectables)
- Endo Pharmaceuticals (specialty injectables)
- West Pharmaceutical Services (injectable delivery systems)
- Hospira / Pfizer Sterile Injectables (injectable generics)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AMPH vs…
Frequently asked questions
What does AMPHASTAR PHARMACEUTICALS INC (AMPH) do?
Amphastar is a biopharmaceutical company that develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredients (APIs). The company currently markets over 25 prescription pharmaceutical products and one over-the-counter product (Primatene MIST®), with major products including BAQSIMI® (nasally administered glucagon for severe hypoglycemia), albuterol sulfate inhalation aerosol,…
What sector is AMPHASTAR PHARMACEUTICALS INC (AMPH) in?
AMPHASTAR PHARMACEUTICALS INC (AMPH) is classified in the Health Care sector. Its industry is Generic and specialty injectable pharmaceuticals / inhalation drugs. It trades on NASDAQ.
Who are AMPHASTAR PHARMACEUTICALS INC's (AMPH) competitors?
Notable peers of AMPHASTAR PHARMACEUTICALS INC (AMPH) include Sandoz (specialty generics and injectables), Baxter International (injectable pharmaceuticals), Hikma Pharmaceuticals (generic injectables), Endo Pharmaceuticals (specialty injectables) and West Pharmaceutical Services (injectable delivery systems). This peer set is informational only — not financial advice.
Is AMPHASTAR PHARMACEUTICALS INC (AMPH) overbought or oversold right now?
AMPHASTAR PHARMACEUTICALS INC (AMPH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 62, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AMPH come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.